These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 26258832)

  • 21. Idarucizumab for dabigatran overdose in a child.
    Shapiro S; Bhatnagar N; Khan A; Beavis J; Keeling D
    Br J Haematol; 2018 Feb; 180(3):457-459. PubMed ID: 27734469
    [No Abstract]   [Full Text] [Related]  

  • 22. Idarucizumab: The Antidote for Reversal of Dabigatran.
    Eikelboom JW; Quinlan DJ; van Ryn J; Weitz JI
    Circulation; 2015 Dec; 132(25):2412-22. PubMed ID: 26700008
    [No Abstract]   [Full Text] [Related]  

  • 23. Reversal of Anticoagulation With Dabigatran in an 82-Year-Old Patient With Traumatic Retroperitoneal Arterial Bleeding Using the New Antidote Idarucizumab: A Case Report.
    Hofer S; Philipsenburg C; Weigand MA; Brenner T
    A A Case Rep; 2016 Dec; 7(11):227-231. PubMed ID: 27669031
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [First new oral anticoagulant with specific antidote].
    Einecke D
    MMW Fortschr Med; 2016 Mar; 158(5):73. PubMed ID: 26979233
    [No Abstract]   [Full Text] [Related]  

  • 25. Idarucizumab: First Global Approval.
    Burness CB
    Drugs; 2015 Dec; 75(18):2155-61. PubMed ID: 26578027
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Successful use of idarucizumab as a reversal agent for dabigatran in a patient with acute dissected aortic aneurysm.
    Tomaszuk-Kazberuk A; Łopatowska P; Młodawska E; van Ryn J; Reilly PA; Pollack CV
    Pol Arch Intern Med; 2017 Jan; 127(1):68-70. PubMed ID: 28146465
    [No Abstract]   [Full Text] [Related]  

  • 27. Idarucizumab for the Reversal of Dabigatran.
    Gottlieb M; Khishfe B
    Ann Emerg Med; 2017 May; 69(5):554-558. PubMed ID: 28110992
    [No Abstract]   [Full Text] [Related]  

  • 28. Volume replacement strategies do not impair the binding of dabigatran to idarucizumab: Porcine model of hemodilution.
    Grottke O; van Ryn J; Zentai C; Gan G; Honickel M; Rossaint R; Ten Cate H; Spronk HMH
    PLoS One; 2019; 14(1):e0209350. PubMed ID: 30615630
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evidence supporting idarucizumab for the reversal of dabigatran.
    Pollack CV
    Am J Emerg Med; 2016 Nov; 34(11S):33-38. PubMed ID: 27697436
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evidence Supporting Idarucizumab for the Reversal of Dabigatran.
    Pollack CV
    Am J Med; 2016 Nov; 129(11S):S73-S79. PubMed ID: 27568285
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intravenous thrombolysis for stroke after Dabigatran reversal with Idarucizumab: an update.
    Cappellari M; Forlivesi S; Squintani GM; Facchinetti R; Bovi P
    J Thromb Thrombolysis; 2017 May; 43(4):528-529. PubMed ID: 28214949
    [No Abstract]   [Full Text] [Related]  

  • 32. [Dabigatran specific antidote: new safety level in oral anticoagulation].
    MMW Fortschr Med; 2015 Nov; 157(19):78-9. PubMed ID: 26953416
    [No Abstract]   [Full Text] [Related]  

  • 33. Reversal by the specific antidote, idarucizumab, of elevated dabigatran exposure in a patient with rectal perforation and paralytic ileus.
    Thorborg C; Horn EP; Mofid H; Langer F
    Br J Anaesth; 2016 Sep; 117(3):407-9. PubMed ID: 27543549
    [No Abstract]   [Full Text] [Related]  

  • 34. Idarucizumab (Praxbind)--an antidote for dabigatran.
    Med Lett Drugs Ther; 2015 Nov; 57(1482):157-8. PubMed ID: 26583604
    [No Abstract]   [Full Text] [Related]  

  • 35. Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatran.
    Pollack CV; Reilly PA; Bernstein R; Dubiel R; Eikelboom J; Glund S; Huisman MV; Hylek E; Kam CW; Kamphuisen PW; Kreuzer J; Levy JH; Sellke F; Stangier J; Steiner T; Wang B; Weitz JI
    Thromb Haemost; 2015 Jul; 114(1):198-205. PubMed ID: 26020620
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [More safe anticoagulant treatment - use of idarucizumab (Praxbind®): case reports from RE-VERSE AD study and clinical practice].
    Tuček D; Veleta T; Havrda M
    Vnitr Lek; 2018; 64(3):309-313. PubMed ID: 29766734
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Anticoagulant activity is rapidly reversed].
    Darius H
    MMW Fortschr Med; 2016 Feb; 158(2):67. PubMed ID: 27017636
    [No Abstract]   [Full Text] [Related]  

  • 38. Reversal of dabigatran anticoagulation ex vivo: Porcine study comparing prothrombin complex concentrates and idarucizumab.
    Honickel M; Treutler S; van Ryn J; Tillmann S; Rossaint R; Grottke O
    Thromb Haemost; 2015 Apr; 113(4):728-40. PubMed ID: 25567155
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Idarucizumab, a Specific Dabigatran Reversal Agent, Reduces Blood Loss in a Porcine Model of Trauma With Dabigatran Anticoagulation.
    Grottke O; Honickel M; van Ryn J; ten Cate H; Rossaint R; Spronk HM
    J Am Coll Cardiol; 2015 Sep; 66(13):1518-9. PubMed ID: 26403349
    [No Abstract]   [Full Text] [Related]  

  • 40. Praxbind Available as Antidote to Bleeding from Pradaxa.
    Aschenbrenner DS
    Am J Nurs; 2016 Jun; 116(6):22-3. PubMed ID: 27227858
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.